Rallybio Corp Stock Price, News & Analysis

AbCellera (Nasdaq: ABCL) and Rallybio Corporation (Nasdaq: RLYB) have announced a strategic alliance aimed at developing novel antibody-based therapeutics for rare diseases. This multi-year collaboration combines AbCellera's advanced antibody discovery capabilities with Rallybio's expertise in rare disease clinical development. The partnership will focus on co-developing up to five therapeutic targets, starting with rare metabolic diseases, addressing significant unmet medical needs. Both companies aim to accelerate drug development and improve patient outcomes.

Rallybio Corporation (RLYB), a clinical-stage biotechnology company, announced its participation in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on December 7, 2022, at 1:40 p.m. ET. The event will be accessible via a live webcast on Rallybio's website, with an archived replay available for 30 days post-event. Founded in January 2018, Rallybio focuses on developing therapies for severe and rare diseases, with a strong portfolio in areas such as hematology and maternal fetal health. The company is headquartered in New Haven, Connecticut.

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company, will participate in two investor conferences: the Jefferies London Healthcare Conference on November 15, 2022, at 8:35 a.m. GMT and the Evercore ISI 5th Annual HealthCONx Conference virtually on November 30, 2022, at 8:25 a.m. EST. Live webcasts will be available on Rallybio's website, with replays accessible for 30 days post-event.

Founded in January 2018, Rallybio focuses on therapies for severe and rare diseases.

Rallybio Corporation (Nasdaq: RLYB) has priced an underwritten public offering of 5,000,001 shares at $6.00 each and pre-funded warrants for up to 3,333,388 shares at $5.9999 each. The total gross proceeds are anticipated to be around $50 million, closing on November 15, 2022. The offering is conducted under the effective shelf registration statement with the SEC, with J.P. Morgan, Cowen, and Evercore ISI as joint lead managers. Investors are advised to refer to the prospectus for detailed information.

Rallybio Corporation (Nasdaq: RLYB) announced a proposed public offering of $75 million in common stock and pre-funded warrants. The offering aims to grant underwriters a 30-day option to purchase an additional 15% of the securities sold. The transaction, which is subject to market conditions, is managed by J.P. Morgan, Cowen, and Evercore ISI. The offering is conducted under an effective shelf registration statement with the SEC, which may affect shareholders. Investors are advised to review the preliminary prospectus for comprehensive details.

Rallybio Corporation (Nasdaq: RLYB) reported financial results for Q3 2022, showing a net loss of $18.4 million and R&D expenses of $12.1 million. The company presented promising preliminary results from the Phase 1b study of RLYB212, demonstrating rapid platelet elimination. Positive topline results from the Phase 1 study of RLYB116 indicated over a 99% reduction in free C5 levels, with potential for less frequent dosing. Rallybio's cash position as of September 30, 2022, was $132.4 million, sufficient to fund operations into Q1 2024.

Rallybio Corporation (Nasdaq: RLYB) has reported positive topline results from its Phase 1 study of RLYB116, a subcutaneous C5 inhibitor. The study demonstrated a reduction of >99% in free C5 within 24 hours after a 100 mg dose in healthy participants, with a terminal elimination half-life exceeding 300 hours. The drug was well-tolerated with mild or moderate adverse events noted. A Phase 1 multiple ascending dose study is set to begin in the first quarter of 2023, potentially leading to improved quality of life for patients with complement-mediated diseases.

Rallybio Corporation announced promising preliminary results from its ongoing Phase 1b study of RLYB212, an anti-HPA-1a monoclonal antibody aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The data indicates that RLYB212 rapidly eliminates transfused HPA-1a positive platelets, achieving over 90% reduction in mean platelet elimination half-life compared to placebo. Safety assessments show acceptable tolerability with no serious adverse events. Rallybio plans to disclose comprehensive proof-of-concept data in the first quarter of 2023.

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology firm, will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference on September 7, 2022, at 3:10 p.m. ET in Everett, MA. A live webcast can be viewed on Rallybio's website, with an archived replay available for 30 days. Founded in January 2018, Rallybio focuses on developing therapies for severe and rare diseases, particularly in hematology and immuno-inflammation. The company is based in New Haven, Connecticut, and collaborates with the University of Connecticut.